3258-02-4|N4-羟基胞苷|N4-Hydroxycytidine|-范德生物科技公司

N4-羟基胞苷

NMR下载 COA and HPLC MSDS下载
names：
N4-Hydroxycytidine
CAS号：
3258-02-4
MDL Number：
MF(分子式)： C3D11PV2O4 MW(分子量)： 259.0804352
EINECS: Reaxys Number:
Pubchem ID:197020 Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	库存描述	数量	总计 (¥)
HCQ000013-1kg	1kg	98.36%	¥ 0.00	¥ 0.00	Get quote	- +	¥ 0.00
HCQ000013-100mg	100mg	98.36%	¥ 18000.00	¥ 18000.00	Instock	- +	¥ 0.00
HCQ000013-50mg	50mg	98.36%	¥ 13200.00	¥ 13200.00	Instock	- +	¥ 0.00
HCQ000013-25mg	25mg	98.36%	¥ 7920.00	¥ 7920.00	Instock	- +	¥ 0.00
HCQ000013-10mg	10mg	98.36%	¥ 4400.00	¥ 4400.00	Instock	- +	¥ 0.00
HCQ000013-5mg	5mg	98.36%	¥ 2800.00	¥ 2800.00	Instock	- +	¥ 0.00
HCQ000013-1mg	1mg	98.36%	¥ 960.00	¥ 960.00	Instock	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	N4-羟基胞苷;4-N-羟基胞苷; β-D-N-4-羟基胞苷； β-D-N4-羟基胞苷； N（4）-羟基胞苷； NHC；尿苷，4-肟; β-D-N4-羟基胞苷
英文别名	4-N-Hydroxycytidine; beta-D-N-4-Hydroxycytidine; Beta-D-N4-hydroxycytidine; N(4)-Hydroxycytidine; NHC; Uridine, 4-oxime; β-D-N4-hydroxycytidine;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)-1,2-dihydropyrimidin-2-one
CAS号	3258-02-4
SMILES	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(NO)=NC1=O
Inchi	InChI=1S/C9H13N3O6/c13-3-4-6(14)7(15)8(18-4)12-2-1-5(11-17)10-9(12)16/h1-2,4,6-8,13-15,17H,3H2,(H,10,11,16)/t4-,6-,7-,8-/m1/s1
InchiKey	XCUAIINAJCDIPM-XVFCMESISA-N
分子式 Formula	C3D11PV2O4
分子量 Molecular Weight	259.0804352
闪点 FP	302.2±32.9 °C
熔点 Melting point	NA
沸点 Boiling point	576.1±60.0 °C at 760 mmHg
Polarizability极化度	21.7±0.5 10-24cm3
密度 Density	1.9±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±3.6 mmHg at 25°C
溶解度Solubility
性状	固体粉末,Powder
储藏条件 Storage conditions	Store at -4℃

Stock Solutions of N4-Hydroxycytidine
Concentration\Solvent\Mass	1mg	5mg	10mg
1 mM	3.8577 mL	19.2886 mL	38.5773 mL
5mM	0.7715 mL	3.8577 mL	7.7155 mL
10mM	0.3858 mL	1.9289 mL	3.8577 mL
DMSO：250 mg / mL（964.43 mM；需要超声）;Water Solubility :34.4 mg/mL

产品说明	A cytidine analog being investigated to treat COVID-19.
Introduction	N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.1,2 N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.5 It has shown antiviral activity against Venezuelan equine encephalitis virus,1 and the human coronavirus HCoV-NL63 in vitro.4 N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.3 It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations.2 In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.6 A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.3 The prodrug of N4-hydroxycytidine, EIDD-2801, is also being investigated for its broad spectrum activity against the coronavirus family of viruses.3
Application1	潜在冠状病毒抑制剂Experimental Unapproved Treatments for COVID-19
Application2
Application3

关于N4-羟基胞苷过量的数据不容易获得。 N4-羟基胞苷对SARS-CoV-2临床分离株的治疗指数有望> 100，体外IC50为0.3µM，CC50> 10µM。

Data regarding overdose of N4-hydroxycytidine is not readily available. The therapeutic index of N4-hydroxycytidine against a clinical isolate of SARS-CoV-2 is expected to be >100, with an in vitro IC50 of 0.3µM and a CC50 of >10µM.

警示图
危险性
危险性警示	Data regarding overdose of N4-hydroxycytidine is not readily available. The therapeutic index of N4-hydroxycytidine against a clinical isolate of SARS-CoV-2 is expected to be >100, with an in vitro IC50 of 0.3μM and a CC50 of >10μM.3
安全声明	NA
安全防护	实验过程防止食如、吸入
备注	NA

Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I: beta-d-N (4)-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. J Virol. 2018 Jan 17;92(3). pii: JVI.01965-17. doi: 10.1128/JVI.01965-17. Print 2018 Feb 1. [PubMed:29167335]

Painter GR, Bowen RA, Bluemling GR, DeBergh J, Edpuganti V, Gruddanti PR, Guthrie DB, Hager M, Kuiper DL, Lockwood MA, Mitchell DG, Natchus MG, Sticher ZM, Kolykhalov AA: The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. 2019 Nov;171:104597. doi: 10.1016/j.antiviral.2019.104597. Epub 2019 Sep 5. [PubMed:31494195]

T. P. Sheahan et al.: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med.. 4.Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P, van der Hoek L: Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8. doi: 10.1128/AAC.01598-05. [PubMed:16723558]

Sledziewska E, Janion C: Mutagenic specificity of N4-hydroxycytidine. Mutat Res. 1980 Mar;70(1):11-6. doi: 10.1016/0027-5107(80)90053-6. [PubMed:7366595]

Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK: Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: 11/515/eaax5866. doi: 10.1126/scitranslmed.aax5866. [PubMed:31645453]

Hampton T: New Flu Antiviral Candidate May Thwart Drug Resistance. JAMA. 2020 Jan 7;323(1):17. doi: 10.1001/jama.2019.20225.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开